The Crofoot Research Center, INC. | ClinicalTrials HQ

7 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance	HIV-1-infection	Active, not recruiting	Phase 2 / Phase 3	2026-10-01		NCT04150068
A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1	HIV-1-infection	Recruiting	Phase 2	2026-09-04		NCT07645287
HIV-1 Virologic Suppression With TMB-365 and TMB-380 Antibodies Study	HIV -1 Infection	Active, not recruiting	Phase 2	2026-08-06		NCT07215468
Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy	HIV-1-infection	Active, not recruiting	Phase 3	2026-06-15		NCT06333808
Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1	HIV-1-Infection	Active, not recruiting	Phase 3	2026-05-29		NCT06630299
Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1	HIV-1-infection	Active, not recruiting	Phase 3	2026-04-30		NCT06630286
Study of Oral Weekly Lepetegravir (Formerly GS-1720) and Lenacapavir Pacfosacil (Formerly GS-4182) Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed	HIV-1-Infection	Active, not recruiting	Phase 2 / Phase 3	2026-04-17		NCT06544733